recent Drospirenone video |
recent Drospirenone articlesunusual vaginal bleeding 
DONT take Yaz if you are allergic to drospirenone or ethinyl estradiol, or if you have: * uncontrolled high blood pressure, migraine headaches, or a heart valve disorder; * a history of stroke, blood clot, or circulation problems of diabetes; * kidney or liver disease; * adrenal gland disorder; * unusual vaginal bleeding; * any type of breast, uterine, or hormone-dependent cancer; or * a history of jaundice caused by birth control pills. Before using Yaz, tell your doctor if you have any of the following conditions. * high blood pressure or heart disease; * high cholesterol or if you are overweight; * liver cancer; * gallbladder disease; * diabetes; * seizures or epilepsy; or * a history of depression, irregular menstrual cycles, or history of breast or uterine cancer.
Author: PlexFilm | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
About Drospirenone
Drospirenone is a synthetic progestin that is an analog to spironolactone, with a molecular weight of 366.5 and the molecular formula C24H30O3. Properties and usesDrospirenone is part of certain birth control formulations. The compound differs from other synthetic progestins in that its pharmacological profile in preclinical studies shows it to be closer to the natural progesterone. As such it has anti-mineralocorticoid properties, counteracts the estrogen-stimulated activity of the renin-angiotensin-aldosterone system, and is not androgenic. With its activities similar to spironolactone it may lead to less water retention and breast tenderness while improving skin appearance (less acne). Drospirenone is taken orally with about 76% bioavailability. It is bound not by sex hormone binding globulin or corticosteroid binding globulin, but by other serum proteins. Metabolites have not been shown to be biologically active, show up in urine and feces, and are essentially completely excreted within 10 days. The compound is part of certain newer oral contraceptive formulations:
It has also been formulated in medication to manage menopausal symptoms using 0.5 mg drsp and 1 mg estradiol per day by oral application. This medication was introduced in the USA in 2007 as Angeliq. Drospirenone at 3mg, which can potentially cause hyperkalemia in high-risk patients, is comparable to a 25mg dose of spironolactone. The medication is contraindicated in patients with hepatic dysfunction, renal insufficiency, adrenal insufficiency, or in whom the use of oral contraceptives is contraindicated, such as smokers and patients with a history of DVT, stroke, or other blood clots. Because of the anti-mineralocorticoid effects care needs to be exercised when other drugs that may increase potassium levels are taken. Such medications include ACE inhibitors, angiotensin-II receptor agonists, potassium-sparing diuretics, potassium supplementation, heparin, aldosterone antagonists, and NSAIDs. See also
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
